JZ
Jonathan Zalevsky sold $7K of NKTR stock
Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), sold 192 shares of NKTR stock worth $7K, per an SEC Form 4 filed Nov 19, 2026.
It was an open-market sale.
The trade happened on Nov 17, 2026, 2 days before it was made public.
NKTR has moved -9.4% since the trade date, from $35.91 to $32.54 (Nov 19, 2026 close).
- Traded
- Nov 17, 2026
- Disclosed
- Nov 19, 2026
- Filing delay
- 2 days
- Price since
- -9.4%
- Role
- Chief R&D Officer
- Source
- SEC Form 4